Zofran Approved for Prevention of RT Emesis
RESEARCH TRIANGLE PARK, NC--Zofran Tablets (ondansetron), from Cerenex Pharmaceuticals, Division of Glaxo Inc., has received FDA approval for a new indication--the prevention of radiation-induced nausea and vomiting. The oral agent, a 5-HT3 antagonist, is currently marketed for prevention of emesis in cancer patients receiving moderately emetogenic chemotherapy.
RESEARCH TRIANGLE PARK, NC--Zofran Tablets (ondansetron), fromCerenex Pharmaceuticals, Division of Glaxo Inc., has receivedFDA approval for a new indication--the prevention of radiation-inducednausea and vomiting. The oral agent, a 5-HT3 antagonist, is currentlymarketed for prevention of emesis in cancer patients receivingmoderately emetogenic chemotherapy.
The specific recommendation is for patients receiving either totalbody irradiation, single high-dose fraction, or daily fractionsto the abdomen. The recommended oral dosage for the new indicationis one 8 mg Zofran Tablet given three times a day. In radiotherapytrials, the most commonly reported side effects of Zofran Tabletswere constipation (6%), headache (5%), and diarrhea (2%).
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
